Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Sock
I'd imagine it was as simple as SIS didn't sell enough of that particular product to turn a decent profit on it, so they dropped it and concentrated on products they thought were more likely to be big sellers and/or be high margin ?
BB
Jatw - it's not really the dilutive effect of the warrants which I was thinking of. It's more what they'll do with the exercised warrants. If General Atlantic exercise the warrants, but then hold the resulting shares, then that'll be great. But, if they exercise then sell into the market, that'll add to the number if shares being traded and might hold the sp back at something a bit north of 30 USD.
So we could see a situation where the ADR price rises to, say, 35USD, General Atlantic exercise, say, 10 million ADRs and sell at prices between 30 and 35 USD. They could rinse and repeat that a fair few times.
I guess a lot depends on the normal volume of trading of ADRs as to whether or not the drip feeding of exercised warrants would have much effect on the sp, and I'll happily admit that I don't know the normal sort of volume of ADRs which get traded is, so I could be typing rubbish here
BB
Nice to see money being raised without effective dilution.
There is one small downside though, in that I think the warrants are likely to effectively put a brake on any share price rises much above 30 USD for 18 months, or sooner if the market can easily handle another 100 million USD worth of ADRs ?
BB
On the A trades - I havn't a clue Alf.
On reducing, I had three profit points ( mentally ) set, it went through the first one, so I followed it. It's a mechanism which has served me well over many years. I tend to ignore stuff like what HNWI's are doing. For every successful Lucas there's likely a McKeeve as well.
Hammer, who posted here, on advfn and iii, used to ( don't think he still does ) work at Asset Match , and he knew far, far more about the markets than I ever will, but it didn't stop him being underwater here for a very long time. Hopefully he's fit, well and showing a profit now though.
Lucas's profile on asset match suggests he might have posted on iii at some time. Must admit, if he did post ( and it is if ) I kind of wonder who he posted as. I suspect he didn't post about Provexis though.
BB
DP64 - he's plainly a pro , knows what he's doing, and is better informed than you or I ( well, me anyway ). That doesn't mean he's always right though, he'll have made plenty of mistakes over the years, it just means he's more likely to be right than your average punter.
As proof of that, I reduced my holding a bit ( roughly a third ) a week or two ago, since when the share price has gone up just over 20% !!
BB
To get that info ...
Open the pdf in Adobe Acrobat Reader
Right click anywhere in the document
Select "Document Properties"
Re the postmark
That sounds right. Using Adobe Reader, the metadata for the document shows it was created on the 9th Nov 2018, and last modified on the 20th Nov 2018
BB
Two things to say to that :-
1. That article's a month old
2. What sort of low life thinks it's a good thing to push their investment on such a tenous link ?
Have a nice life
BB
... to a mid-price of just over 100p.
I ain't complaining, but couldn't see ( via google ), any particular reason for it, no broker upgrades, no tips from anyone really worth reading since Mr Naked Trader, pretty much nada really. I'm struggling to believe that a tip from Motley Fool has that sort of impact ?
tbh - I generally don't file their stuff under Motley, which just leaves Fool.
Has anyone seen anything that I've missed, or is the consensus that we've been marked up because of a mention on MF ?
BB
The trading update confirmed that, although revenues are still growing, we're pretty much low to ex-growth as far as profit grows now. The divi's decent, and I think it's worth holding some Bellway stock purely for the divi, but I've reduced my holding here.
BB
jatw
Like a lot of the recent ChiMed RNS's, it's a Reach RNS so is for info rather than being price sensitive, so that might explain why they're churned out in a fairly generic manner
BB
Sorry to hear about your friend Alf.
Most of us on here are likely fairly mature in years, and with those mature years, comes the downside of losing loved ones more regularly than we used to do, but I'm sure you'll have many happy memories of shared experiences with your friend.
Following on from the last trading update, which had a fairly small profits warning in it, next weeks trading update should be interesting.
If that smallish ( ~ 0.5 million drop in EBITDA ), was just a blip, then I'd expect a bit of a recovery in the share price going forward.
BB - I'm not a holder, but might be one if the update gives a positive outlook for EBIT in 2020
Pumpky - he posted a couple of days ago, so I'd assume he's all right
https://www.lse.co.uk/profiles/alfista/
CB
Re "Sareum" - well, you pays your money and takes your pick, and there are lots of companies on the market, all of which have their own strengths and weaknesses.
Out of interest, was the 1 million sell first thing you exiting / reducing ?
BB
Just had a quick skim through the Interims ...
AA income, which is the important one, was a bit better than I expected.
FF+ was roundabout where I expected, and made a contribution of just over 20k on revenue of roughly 60k. The gross margin, and drop in inventories suggests we havn't had to restock H&B - so it probably isn't flying off the shelves there.
No surprises anywhere else that I can see. All in all, I'm content enough with those numbers as a base for when we start selling to ByHealth
BB
Re "Cut and paste"
Well, yes, doubtless it will be, but the numbers will be different, with, hopefully an increase in revenue from the AA and an increased contribution from FF+
For the corresponding period last year these were 120k and 47k ( top line) respectively, with another 25k or so extra from DSM.
If the first two numbers can be something like 140 to 150k and 60 to 75k respectively then we might end up with reduced losses, which, while we hope for concrete news from China is probably the best we can expect.
BB
dise = dose.
Serves me right for typing about tablets on a bloody tablet !
You get the recommended dise from three tablets a day of the Swanson, as opposed to one tablet a day of the Circulease, so they both provide 30 days worth of Fruitflow.
Or, to put it another way, the Circulease is cheaper